Anthonie J Wekken

9PUBLICATIONS
89CO-AUTHORS
Predictive and prognostic markersEpidemiological modellingMolecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 25, 2026
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

|May 11, 2026
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jul 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.

Fenna de Vries, Eric J F Franssen, Arthur A J Smit

|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Ferdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen

|Apr 14, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.

Weiting Li, Fenneke Zwierenga, Katarina D Andini

Pageof 2

Frequent Collaborators

2 joint publications

Benjamin Besse

2 joint publications

Sai-Hong Ignatius Ou

2 joint publications

Shirish M Gadgeel

2 joint publications

Luis Paz-Ares Rodriguez